ClinicalTrials.gg
RecruitingNCT04291612Updated Aug 7, 2026

Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

An observational study in Endometrial Cancer, Endometrioid Adenocarcinoma and Endometrial Cancer Stage I, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 18 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.

Primary conditionCarcinoma, EndometrioidRegistry: Endometrial NeoplasmsReclassifiedWhy we changed it
Registry
Endometrial Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Endometrioid
Why
  1. The study's listed conditions name Carcinoma, Endometrioid, a narrower term within Endometrial Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

From the registry’s dates

  • Started Feb 2020; still recruiting 6 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,715
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Carcinoma, Endometrioid with a site in United States — 7 open to participants now, 13 under way, 1 of them phase 3. Carcinoma, Endometrioid · United States.

Started
2020
the only one that year
Observational
4 of 32
2 open now
Primary completion
2027-02
later than 6 of 12 live
Registered
21st of 32
by date
Lead sponsor
2 of 32
Memorial Sloan Kettering Cancer Center

Among the 32 studies in Carcinoma, Endometrioid with a site in United States, this one is the only one that started in 2020, is one of 4 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 21st registered.

Carcinoma, Endometrioid

46 studies on the registry are indexed under Carcinoma, Endometrioid; 11 are open to participants now.

Browse Carcinoma, Endometrioid studies →

Open to participants now

7 of the 32 studies in Carcinoma, Endometrioid with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Carcinoma, Endometrioid studies recruiting now, 8 (73%) set no upper age limit and 3 (27%) stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Carcinoma, Endometrioid with a site in United States, or all of them as a file.
02

Study summary

This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.

03

Conditions studied

  • Endometrial Cancer
  • Endometrioid Adenocarcinoma
  • Endometrial Cancer Stage I

Browse trials for

Keywords

  • Endometrial Cancer
  • Endometrioid Adenocarcinoma
  • 20-067
  • Memorial Sloan Kettering Cancer Center
04

In context

Carcinoma, Endometrioid Reclassified

46 studies on the registry are indexed under Carcinoma, Endometrioid; 11 are open to participants now.

Browse Carcinoma, Endometrioid studies →

Lead sponsor

Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.

Compared within Carcinoma, Endometrioid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Endometrial Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Potential research subjects will be identified by a member of the patient's treatment team, the protocol investigator, or a member of the research teams. If the investigator is a member of the treatment team, s/he will screen their patients' medical records for suitable research study participants and discuss the study and their potential for enrolling in the research study. Potential subjects contacted by their treating physician will be referred to the investigator/research staff of the study. The principal investigators may also screen the medical records of patients with whom they do not have a treatment relationship for the limited purpose of identifying patients who would be eligible to enroll in the study, and to record appropriate contact information in order to approach these patients regarding the possibility of enrolling in the study. Patients identified in this manner would subsequently be approached for study enrollment after consultation with their treating physician.

Eligibility criteria

Screening Inclusion Criteria:

  • performance status 0-1 or ≥ 70%
  • Age ≥ 18 years
  • Endometrioid adenocarcinoma histologic diagnosis on endometrial or dilatation and curettage
  • No evidence of extrauterine disease, or suspicious pelvic lymph nodes, or distant , or cervical invasion on pre-operative conventional imaging studies (Pelvic +/- Abdomen CT or MRI or sonogram, or body PET scan) and physical examination (uterine confined by exam and imaging )
  • Suitable candidate for surgery
  • Planned surgical treatment including hysterectomy in combination with SLN biopsy and a bilateral salpingo-oophorectomy
  • No history of second primary cancer (invasive or in situ) within the past 5 years, not including non-melanoma skin cancer
  • Approved and signed
  • No history of chemotherapy or radiotherapy for endometrial cancer
  • No history of prior pelvic or abdominal radiotherapy

Screening Exclusion Criteria:

  • Extrauterine disease, or gross lymph node involvement, or cervical invasion suspected on pre-operative imaging studies and physical examination (disease not uterine confined clinical stage > I)
  • for SLN mapping
  • The planned treatment is not surgery, or the surgical treatment does not include hysterectomy in combination with SLN biopsy and a bilateral salpingo-oophorectomy

Eligibility Inclusion Criteria

Patients will be classified in the study cohort (part 2; n=182) according to surgical treatment received, final post hysterectomy and staging pathologic report, and planned adjuvant treatment. The inclusion criteria are specified below.

Study Cohort (n=182)

A patient will be enrolled in the study cohort if all the following criteria are met:

  • At surgery, the patient must undergo:

    • Hysterectomy
    • Bilateral salpingo-oophorectomy, unless already performed (including allowing unilateral salpingo-oophorectomy if unilateral salpingo-oophorectomy already performed)
    • Bilateral pelvic SLN mapping (bilateral sentinel nodes are negative for )
  • On the final pathologic report, the patient must have a diagnosis of:

    • Stage I intermediate-risk endometrial endometrioid cancer (Grade 1 or Grade 2 with ≥ 50% myometrial invasion or Grade 3 with \<50% myometrial invasion, including non-invasive disease)
    • Negative pelvic peritoneal cytology
  • Adjuvant treatment as recommended by the multidisciplinary team must be as follows:

    • No adjuvant treatment, or
    • Intravaginal radiation only

Eligibility Exclusion Criteria

  • There is intra-operative detection of extra-uterine disease or grossly involved lymph nodes
  • Presence of any positive pelvic nodes including micrometastasis and isolated tumor cells (ITC)
  • Hysterectomy is not performed
  • Bilateral salpingo-oophorectomy is not performed, unless already performed (unilateral salpingo-oophorectomy is allowed if unilateral salpingo-oophorectomy already performed)
  • Failed unilateral or bilateral SLN mapping
  • Patient undergoes a complete unilateral or bilateral pelvic lymphadenectomy
  • Patient undergoes a radical type C hysterectomy
  • Stage IA endometrioid cancer Grade1 or 2 and myometrial invasion \<50%
  • Stage IB Grade 3 endometrioid cancer
  • Non-endometrioid histology: Serous, clear cell, carcinosarcoma, undifferentiated, or de-differentiated histology noted on final hysterectomy pathology
  • Empty unilateral or bilateral sentinel lymph nodal packet(s)
  • Positive peritoneal cytology
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,715 participants (estimated)
Patient registry
No

Groups and cohorts

  • Part 1

    Participants will have endometrioid adenocarcinoma histological diagnosis with planned surgical treatment including hysterectomy in combination with SLN biopsy.

  • Part 2

    Participants will have undergone surgery and bilateral sentinel lymph node mapping (negative for malignancy)

    Other: Physical exam

Interventions

  • OtherPhysical exam

    Part 2 participants will be prospectively followed clinically for relapse for 30 months from the date of surgery for physical examination at post-ops visits.

07

What researchers measure

Primary outcomes

  1. Incidence of pelvic/non-vaginal recurrence at 36 months

    Participants will be assessed every 6 (+/- 2) months for 36 months through routine physical examination

    Time frame: 36 months

08

Study locations

14 of 18 sites recruiting
  • Hartford Healthcare Cancer Institute @ Hartford Hospital
    Hartford, Connecticut 06102, United States
    Recruiting
    • Jonathan Cosin, MD · Contact860-826-1101
  • Miami Cancer Institute Baptist Health South Florida
    Miami, Florida 33143, United States
    Recruiting
    • John Paul Diaz, MD · Contact786-596-2000
  • ADVENTHEALTH (Data collection only)
    Orlando, Florida 32804, United States
    Recruiting
    • Robert Holloway, MD · Contact407-303-2422
  • Mayo Clinic (Data Collection and Data Analysis)
    Rochester, Minnesota 55905, United States
    Active, not recruiting

    Not enrolling at this site.

  • Memorial Sloan Kettering Basking Ridge (All protocol activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Nadeem Abu-Rustum, MD · Contact212-639-7051
  • Memorial Sloan Kettering Monmouth (All protocol activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Nadeem Abu-Rustum, MD · Contact212-639-7051
  • Memorial Sloan Kettering Bergen (All protocol activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Nadeem Abu-Rustum, MD · Contact212-639-7051
  • Memorial Sloan Kettering Commack (All Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Nadeem Abu-Rustum, MD · Contact212-639-7051
  • Memorial Sloan Kettering Westchester (All protocol activities)
    Harrison, New York 10604, United States
    Recruiting
    • Nadeem Abu-Rustum, MD · Contact212-639-7051
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Nadeem Abu-Rustum, MD · Contact212-639-7051
  • Memorial Sloan Kettering Nassau (All protocol activities)
    Rockville Centre, New York 11553, United States
    Recruiting
    • Nadeem Abu-Rustum, MD · Contact212-639-7051
  • Lehigh Valley Health Network
    Allentown, Pennsylvania 18103, United States
    Recruiting
    • Martin Martino, MD · Contact610-402-3650
  • Houston Methodist Cancer Center (Data Collection Only)
    Houston, Texas 77030, United States
    Recruiting
    • Pedro Ramirez, md · Contact713-441-1026
  • Charles University and General University Hospital (Data Collection Only)
    Prague, Czechia
    Terminated

    Not enrolling at this site.

  • OSPEDALE MICHELE E PIETRO (Data Collection Only)
    Ferrera, Italy
    Recruiting
    • Alessandro Buda, MD · Contact0173 290851
  • L'Azienda Sanitaria Universitaria Friuli Centrale
    Udine, Italy
    Recruiting
  • OSLO UNIVERSITY HOSPITAL,RIKSHOPITALET (Data Collection Only)
    Oslo, Norway
    Not yet recruiting
    • Ane Gerda, MD, PhD · Contact+47 22 93 44 46
  • Sulaiman Al Habib Medical Group
    Khobar, Eastern Province, Saudi Arabia
    Not yet recruiting
    • Sarah Al-Rubaish, MD · Contact
09

References and documents

Publications

  • Grassi T, Mariani A, Cibula D, Soliman PT, Suman VJ, Weaver AL, Pedra Nobre S, Weigelt B, Glaser GE, Cappuccio S, Abu-Rustum NR. A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial). Int J Gynecol Cancer. 2020 Oct;30(10):1627-1632. doi: 10.1136/ijgc-2020-001698. Epub 2020 Jul 22. PubMed 32699021 ↗

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2020 (actual). Primary completion is estimated for Feb 2027, 84 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2020
First posted
Mar 2, 2020
StartActual
Feb 26, 2020
Primary completionEst.
Feb 26, 2027
CompletionEst.
Feb 26, 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04291612
Responsible party
Sponsor
First posted
Mar 2, 2020
Start date
Feb 26, 2020
Primary completion
Feb 26, 2027 (estimated)
Completion
Feb 26, 2027 (estimated)
Last update
Aug 7, 2026

Study contacts

Nadeem Abu-Rustum, MD
Contact
abu-rusn@mskcc.org
212-639-7051
Mario Leitao, MD
Contact
leitaom@mskcc.org
212-639-3987
Nadeem Abu-Rustum, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion